Here's your Cheat Sheet to earnings...
Walgreen has performed well over the past year. Is this trend likely to continue?
CVS Caremark is trading near all-time highs on increasing earnings and revenue growth rates, but relative to its peers and sector, it's not doing so well...
Take a closer look at the new ratings and price targets...
What investors need to know...
Express Scripts's Top Institutional Shareholders for Q4 2012
Here are the top trending stocks of the day...
Here's what analysts had to say about these companies today...
Here's what analysts had to say about these companies today...
Take a closer look at the new ratings and price targets...
It's always a good strategy to track transparency of pundits...
Obamacare and the aging population of the country were cited as positive factors...
Here's what analysts had to say about these companies today...
These stocks are attracting tons of trading interest now...
Your Cheat Sheet to the top healthcare business news...
Here's what analysts had to say about these companies today...
See which companies are seeing their stock prices at annual highs right now...
Here's the top trending stocks of the day...
Here's what analysts had to say about these companies today...
October was a little scary for Walgreens, but investors are beginning to get back on board...
After strong third-quarter earnings, is it time to buy into CVS Caremark?
CVS is trading near all-time highs, so it would not be surprising to see investors take profits in the short-term...
Analysis on highly active stocks for investors...
Here's what analysts had to say about these companies today...
Express Scripts said the business environment and unemployment hurt results. In case you were wondering, the poor economic climate led to “depressed drug utilization” by households. This means people are taking less medications compared to last year.
Here's what analysts had to say about these companies today...
Here's a closer look at the company's latest earnings release...
Analysis on highly active stocks for investors...
Here's what you need to know for the upcoming earnings release ...
Worries that Vivus’ new obesity drug would not be widely covered by health insurers have been put to rest...